免疫检查点抑制剂相关移植排斥的药物警戒与文献综述
该研究基于VigiBase数据库进行不成比例分析,并结合系统文献综述,评估ICI相关移植排斥事件的特征。共纳入96例移植排斥报告,以肾移植(65例)和肝移植(23例)为主,主要ICI适应症为恶性黑色素瘤(43.8%)。排斥发生中位时间为21天,后续死亡率为36.5%,肝移植受者死亡率更高(p<0.0001)。
要点
- ICI相关移植排斥多见于肾移植和肝移植受者,中位发生时间21天。
- 纳武利尤单抗、帕博利珠单抗和伊匹木单抗与肾移植排斥相关,纳武利尤单抗与肝移植排斥过报告相关。
- 排斥后死亡率为36.5%,肝移植受者死亡率显著更高。
核心结论
- ICI相关移植排斥主要报告于肾移植和肝移植受者,排斥以T细胞介导为主,体液免疫参与较少。
研究设计与样本
- 基于WHO药物警戒数据库VigiBase进行不成比例分析,并以信息成分(IC)的95%可信区间下限(IC025)阳性为显著。
- 结合系统文献综述纳入96例ICI后移植排斥报告,包括肾65例、肝23例、角膜2例、心脏5例。
主要发现
- ICI主要适应症为恶性黑色素瘤(39/89,43.8%),首次ICI给药至排斥发生时间为21天(四分位距:13;56)。
- 肾移植排斥与纳武利尤单抗(IC025=1.32)、帕博利珠单抗(IC025=1.17)和伊匹木单抗(IC025=0.33)相关。
- 肝移植排斥主要与纳武利尤单抗过报告相关(IC025=1.95)。
- 抗PD-1和抗PD-L1药物较抗CTLA-4药物更常涉及(93.0% vs 7.0%)。
- 后续死亡率为36.5%,肝移植受者高于其他器官受者(p<0.0001);活检均报告急性细胞性排斥,仅少数(6/28,21.4%)伴抗体介导病变。
关键数值与推荐
- IC025阳性定义为显著,肾移植排斥纳武利尤单抗IC025=1.32、帕博利珠单抗IC025=1.17、伊匹木单抗IC025=0.33。
- 肝移植排斥纳武利尤单抗IC025=1.95。
- 抗PD-1/PD-L1涉及93.0%,抗CTLA-4涉及7.0%。
- 排斥后死亡率36.5%,肝移植受者与其他器官受者比较p<0.0001。
- 活检急性细胞性排斥中伴抗体介导病变者6/28(21.4%)。
临床怎么用
- 对接受ICI的移植受者应警惕移植排斥,尤其肾移植和肝移植受者。
- 排斥发生中位时间约21天,早期监测肾功能和肝功能可能有助于及时发现。
- 处理以静脉糖皮质激素冲击和停用ICI为主,肝移植受者排斥后死亡风险更高。
局限性
- 基于自发报告的药物警戒数据可能存在报告偏倚和混杂因素。
- 文献综述部分病例报告信息有限,治疗管理和病理结果不完整。
- 样本量有限(96例),部分器官类型例数较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Solid organ transplant recipients are at increased risk of cancer due to long-term immunosuppression. Immune-checkpoint inhibitors (ICI) showed clinical benefits but increased risk of transplant rejection. Our work aims to assess the main features of reported rejection events. METHODS: A disproportionality analysis of the World Health Organisation pharmacovigilance database, VigiBase, to identify drugs associated with rejection events. The estimate of this analysis is the information component for which the lower end of the 95% credibility interval (IC025) indicates significance when positive. We combined a systematic literature review of case reports to obtain additional information regarding treatment management and histopathological findings. RESULTS: A total of 96 reports of transplant rejections following ICI were included, including kidney (n = 65), liver (n = 23), cornea (n = 2) and heart (n = 5). The main indication reported for ICI was malignant melanoma (39/89, 43.8%). The time to onset between first ICI administration and rejection was 21 [interquartile range: 13; 56] days. Kidney transplant rejection was associated with nivolumab (IC025 = 1.32), pembrolizumab (IC025 = 1.17) and ipilimumab (IC025 = 0.33); while liver transplant rejection was mostly over-reported with nivolumab (IC025 = 1.95). Overall, anti-PD-1 and anti-PD-L1 were more involved than anti-CTLA-4 drugs (93.0% versus 7.0%). Subsequent mortality was 36.5% and involved liver-transplant recipients more than other organ recipients (p < 0.0001). When performed, all biopsies reported acute cellular rejections, but only a few showed concomitant antibody-mediated lesions (6/28, 21.4%). Management mainly consisted in intravenous corticosteroid boluses and ICI cessation. CONCLUSION: ICI-associated transplant rejections were mostly reported in kidney and liver transplant recipients. Rejections were T-cell mediated with low participation of humoral response.
引用
- Nguyen LS, Ortuno S, Lebrun-Vignes B, et al. Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review. Eur J Cancer. 2021. PMID: 33721705. doi:10.1016/j.ejca.2021.01.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。